• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Hematology

Inflammatory bowel disease may increase risk of venous thromboembolism in children

bySimon PanandAlex Chan
March 12, 2025
in Hematology, Pediatrics
Reading Time: 2 mins read
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Share on FacebookShare on Twitter

1. Children living with inflammatory bowel disease (IBD) are at greater risk of venous thromboembolism (VTE) compared to children without VTE, with the highest risk occurring around time of diagnosis. 

Evidence Rating Level: 2 (Good)

Evidence from recent studies suggest that children living with IBD are at greater risk of VTE compared to children without IBD. However, due to the rarity of VTE in IBD patients in spite of this increased risk, studies have been limited to a lower number of events, making it difficult to characterize VTE risk in children beyond incidence rates. This study therefore sought to characterize children with IBD who develop VTE and to calculate absolute and relative risks compared to the general population. Patients under the age of 18 with IBD between 2001 and 2019 were identified via HES, a nationwide administrative database of all hospitals in England. A comparator cohort was constructed using data from children without IBD from the Office for National Statistics as well as HES data. The absolute risk of VTE in the general pediatric population was 0.18 (95% confidence interval [CI], 0.18-0.19) per 10,000 patient-years, while it was 9.42 (95% CI, 7.4-11.4) per 10 000 patient-years for pediatric patients living with IBD. Among children living with IBD, there was an overall relative risk increase of 51.8 (95% CI, 41.8-64.3) compared to children without IBD. When analyzing based on demographic factors, children with ulcerative colitis were at a higher risk for VTE compared to children with Crohn’s disease (incidence rate 12.4 vs 5.6 per 10 000 patient-years). Among children with IBD and VTE, 65 (76.5%) developed a VTE either within the first year following IBD diagnosis or 6 months prior to IBD diagnosis. Overall, this study found that children living with IBD are at increased risks of developing a VTE, with the greatest risk occurring around the time of diagnosis.

Click to read the study in the study in Inflammatory Bowel Disease 

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

RELATED REPORTS

Prognostic associations of anthropometric indices vary by clinical outcomes

Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma

Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome

Previous Post

Poor control over clinical work associated with burnout among physicians

Next Post

#VisualAbstract: Tenecteplase is Non-Inferior to Alteplase for Acute Ischemic Stroke within 4.5 Hours of Onset

RelatedReports

Cardiology

Prognostic associations of anthropometric indices vary by clinical outcomes

September 28, 2026
Chronic Disease

Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma

September 28, 2026
Chronic Disease

Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome

September 28, 2026
Weekly Rewinds

2 Minute Medicine Rewind September 28, 2026

September 28, 2026
Next Post
#VisualAbstract: Tenecteplase is Non-Inferior to Alteplase for Acute Ischemic Stroke within 4.5 Hours of Onset

#VisualAbstract: Tenecteplase is Non-Inferior to Alteplase for Acute Ischemic Stroke within 4.5 Hours of Onset

Study lends support for interferon-free treatment of hepatitis C

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding

Endometriosis and uterine fibroids associated with a greater risk of mortality due to gynecologic cancers

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
  • Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.